FrancophonIA/ELRC3.0 huggingface dataset:
English: For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of Uptravi should be 200 micrograms once daily, and increased at weekly intervals by increments of 200 micrograms given once daily until adverse reactions, reflecting the mode of action of selexipag, that cannot be tolerated or medically managed are experienced.
Maltese: Għal pazjenti b'indeboliment moderat tal-fwied (Child-Pugh klassi B), id-doża tal-bidu ta' Uptravi għandha tkun 200 mikrogramma darba kuljum, u għandha tiżdied f'intervalli ta' kull ġimgħa b'inkrementi ta' 200 mikrogramma mogħtija darba kuljum sakemm iseħħu reazzjonijiet avversi, li jirriflettu l-mod ta' azzjoni ta' selexipag, li ma jistgħux jiġu ttollerati jew immaniġġjati medikament.
English: Uptravi 200 microgram film-coated tablets contain 200 micrograms of selexipag Uptravi 400 microgram film-coated tablets contain 400 micrograms of selexipag Uptravi 600 microgram film-coated tablets contain 600 micrograms of selexipag Uptravi 800 microgram film-coated tablets contain 800 micrograms of selexipag Uptravi 1,000 microgram film-coated tablets contain 1,000 micrograms of selexipag Uptravi 1,200 microgram film-coated tablets contain 1,200 micrograms of selexipag Uptravi 1,400 microgram film-coated tablets contain 1,400 micrograms of selexipag Uptravi 1,600 microgram film-coated tablets contain 1,600 micrograms of selexipag
Maltese: Uptravi 200 mikrogramma pilloli miksija b'rita fihom 200 mikrogramma ta' selexipag Uptravi 400 mikrogramma pilloli miksija b'rita fihom 400 mikrogramma ta' selexipag Uptravi 600 mikrogramma pilloli miksija b'rita fihom 600 mikrogramma ta' selexipag Uptravi 800 mikrogramma pilloli miksija b'rita fihom 800 mikrogramma ta' selexipag Uptravi 1,000 mikrogramma pilloli miksija b'rita fihom 1,000 mikrogramma ta' selexipag Uptravi 1,200 mikrogramma pilloli miksija b'rita fihom 1,200 mikrogramma ta' selexipag Uptravi 1,400 mikrogramma pilloli miksija b'rita fihom 1,400 mikrogramma ta' selexipag Uptravi 1,600 mikrogramma pilloli miksija b'rita fihom 1,600 mikrogramma ta' selexipag
English: Uptravi should be used with caution in this age group.
Maltese: Uptravi għandu jintuża b'attenzjoni f'dan il-grupp ta' età.
English: The safety and efficacy of Uptravi in children aged 0 to less than 18 years have not yet been established.
Maltese: Is-sigurtà u l-effikaċja ta' Uptravi fit-tfal ta' età minn 0 sa inqas minn 18-il sena għadhom ma ġewx determinati s'issa.
English: Round, light-violet, film-coated tablets with “6” debossed on one side.
Maltese: Pilloli miksija b'rita, tondi, vjola ċari, b'“6” immarkat fuq naħa waħda.
English: Uptravi 1,400 microgram film-coated tablets.
Maltese: Uptravi 1,400 mikrogramma pilloli miksija b'rita.
English: Uptravi 1,400 microgram film-coated tablets contain iron oxide yellow (E172).
Maltese: Uptravi 1,400 mikrogramma pilloli miksija b'rita fihom iron oxide isfar (E172).
English: Hypromellose, propylene glycol, titanium dioxide (E171), carnauba wax and iron oxides (see below).
Maltese: Hypromellose, propylene glycol, titanium dioxide (E171), carnauba wax u iron oxides (ara hawn taħt).
English: Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide red (E172), carnauba wax.
Maltese: Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide isfar (E172), carnauba wax.
English: The dose is increased in increments of 200 micrograms given twice daily, usually at weekly intervals.
Maltese: Id-doża tiġi miżjuda f'inkrementi ta' 200 mikrogramma mogħtija darbtejn kuljum, normalment f'intervalli ta' ġimgħa.
English: Uptravi 400 microgram film-coated tablets contain iron oxide red (E172).
Maltese: Uptravi 400 mikrogramma pilloli miksija b'rita fihom iron oxide aħmar (E172).
English: 10 film-coated tablets 60 film-coated tablets
Maltese: 10 pilloli miksija b'rita 60 pillola miksija b'rita
English: Uptravi 800 microgram film-coated tablets contain iron oxide yellow and iron oxide black (E172).
Maltese: Uptravi 800 mikrogramma pilloli miksija b'rita fihom iron oxide isfar u iron oxide iswed (E172).
English: Uptravi 200 microgram film-coated tablets.
Maltese: Uptravi 200 mikrogramma pilloli miksija b'rita.
English: Selexipag This medicine is subject to additional monitoring.
Maltese: Dan il-prodott mediċinali huwa suġġett għal monitoraġġ addizzjonali.
English: In the Phase 3 placebo-controlled trial in patients with PAH, the use of selexipag in combination with both an ERA and a PDE-5 inhibitor resulted in a 30% lower exposure to the active metabolite.
Maltese: Fil-prova ta' Fażi 3 ikkontrollata bil-plaċebo f'pazjenti b'PAH, l-użu ta' selexipag flimkien ma' inibitur ta' ERA u ta' PDE-5 wassal għal tnaqqis ta' 30% fl-esponiment għall-metabolit attiv.
English: During titration, you may experience side effects such as headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face (see section 4).
Maltese: Waqt it-titrazzjoni, jista' jkollok effetti sekondarji bħal uġigħ ta' ras, dijarea, tħossok imdardar (tqalligħ), tirremetti, uġigħ fix-xedaq, uġigħ fil-muskoli, uġigħ fir-riġlejn, uġigħ fil-ġogi, jew ħmura fil-wiċċ (ara sezzjoni 4).
English: Uptravi 1,000 microgram film-coated tablet
Maltese: Uptravi 1,000 mikrogramma pillola miksija b'rita
English: PAH-specific therapy.
Maltese: dan il-fuljett.
English: Uptravi 400 microgram film-coated tablets.
Maltese: Uptravi 400 mikrogramma pilloli miksija b'rita.
English: Like all medicines, Uptravi can cause side effects.
Maltese: Bħal kull mediċina oħra, Uptravi jista' jikkawża effetti sekondarji.
English: Uptravi 1,600 microgram film-coated tablet
Maltese: Uptravi 1,600 mikrogramma pillola miksija b'rita
English: Uptravi 400 microgram film-coated tablet
Maltese: Uptravi 400 mikrogramma pillola miksija b'rita
English: • Patient titration guide;
Maltese: phosphodiesterase tip 5.
English: During dose titration some adverse reactions, reflecting the mode of action of Uptravi (such as headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing), may occur.
Maltese: Matul titrazzjoni tad-doża jistgħu jseħħu xi reazzjonijiet avversi, li jirriflettu l-mod ta' azzjoni ta' Uptravi (bħal uġigħ ta' ras, dijarea, dardir u rimettar, uġigħ fix-xedaq, mijalġja, uġigħ fl-estremitajiet, artralġja, u fwawar).
English: If you experience any of these side effects: headache, diarrhoea, feeling sick (nausea), being sick (vomiting), jaw pain, muscle pain, leg pain, joint pain, or reddening of the face, that you cannot tolerate or that cannot be treated, you should contact your doctor as the dose you are taking maybe too high for you and may need to be reduced.
Maltese: Jekk ikollok xi wieħed minn dawn l-effetti sekondarji: uġigħ ta' ras, dijarea, tħossok imdardar (tqalligħ), tirremetti, uġigħ fix-xedaq, uġigħ fil-muskoli, uġigħ fir-riġlejn, uġigħ fil-ġogi, jew ħmura fil-wiċċ, li inti ma tistax tittollera jew li ma jistgħux jiġu ttrattati, għandek tikkuntattja lit-tabib tiegħek għax id-doża li tkun qed tieħu tista' tkun għolja wisq għalik u jista' jkollha bżonn titnaqqas.
English: Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172), carnauba wax.
Maltese: Hypromellose, propylene glycol, titanium dioxide (E171), iron oxide isfar (E172), iron oxide iswed (E172), carnauba wax.
English: Uptravi 1,600 microgram film-coated tablets.
Maltese: Uptravi 1,600 mikrogramma pilloli miksija b'rita.
English: Uptravi 600 microgram film-coated tablets.
Maltese: Uptravi 600 mikrogramma pilloli miksija b'rita.
English: There is limited clinical experience in patients over the age of 75 years, therefore Uptravi should be used with caution in this population (see section 4.4).
Maltese: Hemm esperjenza klinika limitata f'pazjenti ta' età 'l fuq minn 75 snin, għalhekk Uptravi għandu jintuża b'attenzjoni f'din il-popolazzjoni (ara sezzjoni 4.4).
English: Revert to twice daily dosing frequency of Uptravi when co-administration of moderate CYP2C8 inhibitor is stopped (see section 4.5).
Maltese: Wieħed għandu jerġa' jmur lura għal frekwenza tad-dożaġġ ta' Uptavi ta' darbtejn kuljum meta l-għoti flimkien ma' inibituri moderati ta' CYP2C8 jitwaqqaf (ara sezzjoni 4.5).
English: Uptravi 1,000 microgram film-coated tablets.
Maltese: Uptravi 1,000 mikrogramma pilloli miksija b'rita.
English: Uptravi 600 microgram film-coated tablets
Maltese: Uptravi 600 mikrogramma pillola miksija b'rita
English: Talk to your PAH doctor or nurse before taking Uptravi if you - are taking medicines for high blood pressure - have low blood pressure associated with symptoms such as dizziness - have recently experienced significant blood loss or fluid loss such as severe diarrhoea or vomiting - have problems with your thyroid gland - have severe problems with your kidneys or are undergoing dialysis - have or have had severe problems with your liver not working properly
Maltese: Kellem lit-tabib jew lill-infermier tiegħek tal-PAH qabel tieħu Uptravi jekk inti - qed tieħu mediċini għall-pressjoni għolja - għandek pressjoni baxxa assoċjata ma' sintomi bħal sturdament - reċentement kellek telf sinifikanti ta' demm jew ta' fluwidu bħal dijarea jew rimettar severi - għandek problemi bil-glandola tat-tirojde tiegħek - għandek problemi severi bil-kliewi tiegħek jew qed tagħmel id-dijalisi - għandek jew kellek problemi severi bil-fwied tiegħek li ma jkunx qed jaħdem kif suppost
English: CI = confidence interval; EOT = end of treatment; HR = hazard ratio; i.v.
Maltese: HR = proporzjon ta' periklu; i.v. = fil-vini;
English: ↓When should you step down?
Maltese: Kif għandek tieħu Uptravi?
English: Do not take Uptravi
Maltese: X'fih Uptravi
English: If you have been prescribed both 200 and 800 microgram tablets, use pages 30 to 37 (steps 5-8).
Maltese: 800 mikrogramma, uża paġni 30 sa 37
English: Uptravi 200 microgram film-coated tablets contain iron oxide yellow (E172).
Maltese: Uptravi 200 mikrogramma pilloli miksija b'rita fihom iron oxide isfar (E172).
English: Consequently, if signs of pulmonary oedema occur when Uptravi is administered in patients with PAH, the possibility of pulmonary veno-occlusive disease should be considered.
Maltese: Każijiet ta' edima pulmonari kienu rrappurtati b'vażodilataturi (l-aktar prostacyclins) meta użati f'pazjenti b'marda veno-okklussiva tal-pulmun.
English: The most commonly reported adverse reactions are headache, diarrhoea, nausea and vomiting, jaw pain, myalgia, pain in extremity, arthralgia, and flushing.
Maltese: Ir-reazzjonijiet avversi rrappurtati bl-aktar mod komuni huma uġigħ ta' ras, dijarea, dardir u rimettar, uġigħ fix-xedaq, mijalġja, uġigħ fl-estremitajiet, artralġja, u fwawar.
English: The majority of these reactions are of mild to moderate intensity.
Maltese: Il-maġġoranza ta' dawn ir-reazzjonijiet huma ta' intensità ħafifa sa moderata.
English: Uptravi 200 microgram film-coated tablets
Maltese: Uptravi 200 mikrogramma pillola miksija b'rita
English: In the presence of 600 mg gemfibrozil, twice a day, a strong inhibitor of CYP2C8, exposure to selexipag increased approximately 2-fold, whereas exposure to the active metabolite, the major contributor to efficacy, increased approximately 11-fold.
Maltese: Fil-preżenza ta' 600 mg gemfibrozil, darbtejn kuljum, inibitur qawwi ta' CYP2C8, l-esponiment għal selexipag żdied b'madwar darbtejn, filwaqt li l-esponiment għall-metabolit attiv tiegħu, il-kontributur ewlieni għall-effikaċja, żdied b'madwar 11-il darba.
English: More subjects reported adverse events after administration in the fasted than in the fed state.
Maltese: Aktar individwi rrappurtaw avvenimenti avversi wara għoti fi stat sajjem milli fi stat mitmugħ.
English: Only two subjects with severe (Child-Pugh class C) hepatic impairment were dosed with selexipag.
Maltese: Żewġ individwi b'indeboliment sever tal-fwied (Child-Pugh klassi Ċ) biss kienu iddożati b'selexipag.
English: For a full list of side effects see package leaflet for further information.
Maltese: Jista' jkun li mhux il-pakketti tad-daqsijiet kollha jkunu fis-suq.
English: Uptravi 400 microgram film-coated tablets Each film-coated tablet contains 400 micrograms of selexipag.
Maltese: Uptravi 400 mikrogramma pilloli miksija b'rita Kull pillola miksija b'rita fiha 400 mikrogramma ta' selexipag.
English: The overall median double-blind treatment duration was 63.7 weeks for the placebo group and 70.7 weeks for the selexipag group.
Maltese: It-tul globali medjan ta' trattament double-blind kien ta' 63.7 ġimgħat għall-grupp tal-plaċebo u
English: Uptravi film-coated tablets selexipag
Maltese: Uptravi pilloli miksija b'rita selexipag
English: • The Summary of Product Characteristics for Uptravi;
Maltese: • Is-Sommarju tal-Karatteristiċi tal-Prodott għal Uptravi;
English: Common side effects (may affect up to 1 in 10 people) - Anaemia (low red blood cell levels) - Hyperthyroidism (overactive thyroid gland) - Decreased appetite - Weight loss - Hypotension (low blood pressure) - Stomach pain - Pain - Changes in some blood test results including those measuring blood cell counts or your thyroid function - Rashes, including hives, may cause a burning or stinging sensation and skin redness
Maltese: Effetti sekondarji komuni (jistgħu jaffettwaw sa persuna waħda minn kull 10) - Anemija (livelli baxxi ta' ċelluli ħomor tad-demm) - Ipertirojdiżmu (glandola tat-tirojde attiva żżejjed)
English: Talk to your doctor or nurse if you have side effects.
Maltese: Kellem lit-tabib jew l-infermier tiegħek jekk ikollok effetti sekondarji.
English: Uptravi 1,400 microgram film-coated tablets Round, dark-yellow, film-coated tablets with “14” debossed on one side.
Maltese: Uptravi 1,400 mikrogramma pilloli miksija b'rita Pilloli miksija b'rita, tondi, sofor skuri, b'“14” imnaqqax fuq naħa waħda.
English: Adverse reactions obtained from the pivotal clinical study are tabulated below.
Maltese: Ir-reazzjonijiet avversi miksuba mill-istudju kliniku pivitali huma ppreżentati fit-tabella hawn taħt.
English: Titration diary
Maltese: Dijarea Dardir
English: Dosing frequency of Uptravi should be reduced to once daily when co-administered with moderate CYP2C8 inhibitors (e.g., clopidogrel, deferasirox, teriflunomide).
Maltese: CYP2C8 (eż., clopidogrel, deferasirox, teriflunomide).
English: Uptravi 1,000 microgram film-coated tablets Each film-coated tablet contains 1,000 micrograms of selexipag.
Maltese: Uptravi 1,000 mikrogramma pilloli miksija b'rita Kull pillola miksija b'rita fiha 1,000 mikrogramma ta' selexipag.
English: The efficacy of selexipag on the primary endpoint was consistent across subgroups of age, sex, race, aetiology, geographical region, WHO FC, and as monotherapy or in combination with an ERA or a PDE-5 inhibitor or triple combination with both an ERA and a PDE-5 inhibitor.
Maltese: razza, etjoloġija, reġjun ġeografiku, WHO FC, u bħala monoterapija jew f'kombinazzjoni ma' ERA
English: In the 2-year carcinogenicity studies, selexipag caused an increased incidence of thyroid adenomas in mice and Leydig cell adenomas in rats.
Maltese: Fl-istudji dwar ir-riskju ta' kanċer li damu sentejn, selexipag ikkawża żieda fl-inċidenza ta' adenomi tat-tirojde fil-ġrieden u adenomi taċ-ċelluli Leydig fil-firien.
English: How to store Uptravi
Maltese: Twissijiet u prekawzjonijiet
English: After multiple-dose administration, steady state conditions of selexipag and the active metabolite were reached within 3 days.
Maltese: Wara għoti ta' dożi multipli, il-kondizzjonijiet fi stat fiss ta' selexipag u tal-metabolit attiv intlaħqu fi żmien 3 ijiem.
English: Uptravi 600 microgram film-coated tablets Each film-coated tablet contains 600 micrograms of selexipag.
Maltese: Uptravi 600 mikrogramma pilloli miksija b'rita Kull pillola miksija b'rita fiha 600 mikrogramma ta' selexipag.
English: Thyroid function tests
Maltese: DATA TA' REVIŻJONI TAT-TEST
English: • Headache • Diarrhoea • Nausea • Vomiting • Jaw pain • Muscle pain • Leg pain • Joint pain • Facial redness
Maltese: Il-professjonisti tal-kura tas-saħħa huma mitluba jirrappurtaw kwalunkwe reazzjoni avversa suspettata permezz tas-sistema ta' rappurtar nazzjonali imniżżla f'Appendiċi V.
English: The beneficial effect of selexipag was primarily attributable to a reduction in hospitalisation for PAH and a reduction in other disease-progression events (Table 1).
Maltese: L-effett ta' benefiċċju ta' selexipag kien primarjament attribwibbli għal tnaqqis fid-dħul l-isptar minħabba PAH u tnaqqis f'avvenimenti ta' progressjoni tal-marda oħra (Tabella 1).
English: • Healthcare professional A4 laminated titration guide;
Maltese: • Linja gwida dwar it-titrazzjoni għall-pazjent;
English: The pharmacokinetics of selexipag and its active metabolite have been studied primarily in healthy subjects.
Maltese: Il-farmakokinetika ta' selexipag u tal-metabolit attiv tiegħu ġiet studjata primarjament f'individwi f'saħħithom.
English: Your doctor will prescribe a suitable tablet strength for your maintenance dose.
Maltese: Din id-doża se tkun id-doża ta' manteniment tiegħek.
English: Uptravi 1,200 microgram film-coated tablets Each film-coated tablet contains 1,200 micrograms of selexipag.
Maltese: Uptravi 1,200 mikrogramma pilloli miksija b'rita Kull pillola miksija b'rita fiha 1,200 mikrogramma ta' selexipag.
English: Dose adjustment of selexipag may be required with concomitant administration of inducers of CYP2C8 (e.g., rifampicin, carbamazepine, phenytoin).
Maltese: rifampicin, carbamazepine, phenytoin).
English: Very common side effects (may affect more than 1 in 10 people) - Headache - Flushing (reddening of the face) - Nausea and vomiting (feeling sick and being sick) - Diarrhoea - Jaw pain, muscle pain, joint pain, leg pain - Nasopharyngitis (stuffy nose)
Maltese: Effetti sekondarji komuni ħafna (jistgħu jaffettwaw aktar minn persuna waħda minn kull 10) - Uġigħ ta' ras - Fwawar (ħmura fil-wiċċ)
English: Uptravi 800 microgram film-coated tablets Round, green, film-coated tablets with “8” debossed on one side.
Maltese: Pilloli miksija b'rita, tondi, ħodor, b'“8” immarkat fuq naħa waħda.
English: Control n=124
Maltese: Kontroll n=124
English: IMMUNOSUPPRESSANTS Ciclosporin
Maltese: IMMUNOSOPPRESSANTI Cyclosporin
English: ANTIFUNGALS Voriconazole
Maltese: ANTIFUNGALI Voriconazole
English: Last Observation Carried Forward imputation
Maltese: Imputazzjoni ta' Last Observation Carried Forward
English: Midazolam(oral) Triazolam
Maltese: Midazolam (orali) Triazolam
English: 15 kg to < 20 kg N=16
Maltese: 15 kg sa < 20 kg N=16
English: ARTEMIS Week 192
Maltese: ARTEMIS Ġimgħa 192
English: Treatment difference (95% CI of difference)
Maltese: Differenza fil-kura (95% CI taddifferenza)
English: darunavir /ritonavir 10 kg to < 15 kg N=5
Maltese: darunavir/ritonavir 10 kg sa < 15 kg N=5
English: with darunavir/cobicistat 800/150 mg
Maltese: b'darunavir/cobicistat 800/150 mg
English: PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS
Maltese: TA' PHOSPHODIESTERASE, TAT-TIP 5 (PDE-5)
English: ANAESTHETIC Alfentanil
Maltese: ANESTETIKU Alfentanil
English: SEDATIVES/HYPNOTICS
Maltese: SEDATTIVI/IPNOTIĊI
English: The most frequent adverse reactions reported were diarrhoea (28%), nausea (23%), and rash (16%).
Maltese: L-aktar reazzjonijiet avversi frekwenti li ġew irrappurtati kienu dijarea (28%), nawsja (23%), u raxx (16%).
English: HMG CO-A REDUCTASE INHIBITORS Lovastatin
Maltese: IMPEDITURI TA' HMG CO-A REDUCTASE Lovastatin
English: Type AE Type C
Maltese: Tip AE
English: Tablet dimension: 17 x 8.5 mm.
Maltese: Dimensjoni tal-pillola: 17 x 8.5 mm.
English: Summary of the safety profile
Maltese: Sommarju tal-profilta'sigurtà
English: α1-ADRENORECEPTOR ANTAGONIST Alfuzosin
Maltese: ANTAGONIST TAL-ADRENORIĊETTUR α1 Alfuzosin
English: 100 milligram between 30 and 40 kilograms 675 milligram
Maltese: 100 milligramma bejn 30 u 40 kilogramma 675 milligramma
English: 800 milligram
Maltese: 600 milligramma
English: Ethinylestradiol Norethindrone 35 μg/1 mg once daily
Maltese: Ethinylestradiol Norethindrone 35 μg/1 mg darba kuljum
English: Disopyramide Flecainide Lidocaine (systemic) Mexiletine Propafenone
Maltese: Lidocaine (sistemiku) Mexiletine Propafenone
English: C-darunavir with ritonavir dose, approximately 79.5% and 13.9% of the administered dose of
Maltese: C-darunavir ma' ritonavir, bejn wieħed u ieħor 79.5% u 13.9% tad-doża amministrata ta'
English: ANTICONVULSANTS Phenobarbital Phenytoin
Maltese: ANTIKONVULŻIVI Phenobarbital Phenytoin
English: 6/l (see section 4.2 and 4.4).
Maltese: 6/l (ara sezzjoni 4.2 u 4.4).
English: However, unbound darunavir concentrations were approximately 55% (Child-Pugh Class A) and 100% (ChildPugh Class B) higher, respectively.
Maltese: Madankollu, konċentrazzjonijiet ta' darunavir mhux imwaħħla mal-proteini kienu bejn wieħed u ieħor 55% (Child-Pugh Klassi A) u 100% (Child-Pugh Klassi B) ogħla rispettivament.
English: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straβe 5, 27472 Cuxhaven, Germany
Maltese: KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Is-Slovenja TAD Pharma GmbH, Heinz-Lohmann-Straβe 5, 27472 Cuxhaven, Il-Ġermanja
English: CCR5 ANTAGONIST Maraviroc
Maltese: TA' CCR5 Maraviroc
English: ANTIMYCOBACTERIALS Rifampicin
Maltese: ANTIMIKOBATTERIĊI Rifampicin
English: Musculoskeletal abnormalities
Maltese: Anormalitajiet muskoluskeletriċi
English: H2-RECEPTOR ANTAGONISTS Ranitidine
Maltese: H2 Ranitidine
English: Dapoxetine to treat premature ejaculation
Maltese: TRATTAMENT GĦAL EĠAKULAZZJONI PREMATURA Dapoxetine
English: (P-gp, BCRP and/or OATP1B1/3 inhibition)
Maltese: (P-gp, inibizzjoni ta' BCRP u/jew OATP1B1/3)
English: HERBAL PRODUCTS St John's wort (Hypericum perforatum)
Maltese: St John's wort (Hypericum perforatum)
English: ANTINEOPLASTICS
Maltese: ANTINEOPLASTIĊI
English: Tablet dimension: 20 x 10 mm.
Maltese: Dimensjoni tal-pillola: 20 x 10 mm.
English: Total number of virologic failures a, n (%)
Maltese: Numru totali ta' fallimenti viroloġiċi a, n (%)
English: Tablet dimension: 19.5 x 10 mm.
Maltese: Dimensjoni tal-pillola: 19.5 x 10 mm.
English: Infections and infestations uncommon herpes simplex
Maltese: Infezzjonijiet u infestazzjonijiet mhux komuni herpes simplex
English: ODIN Week 48
Maltese: ODIN Ġimgħa 48
English: Efavirenz (HIV infection)
Maltese: Efavirenz (għal infezzjoni bl-HIV)
English: Tabulated list of adverse reactions
Maltese: Lista tabulatatar-reazzjonijiet avversi
English: Corticosteroids including betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
Maltese: - Kortikosterojdi inkluż betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone.
English: Flurazepam Midazolam (parenteral) Zoldipem
Maltese: Midazolam (parenterali) Zoldipem
English: Nucleo(s/t)ide reverse transcriptase inhibitors (NRTIs) Didanosine
Maltese: Impedituri ta' nucleo(s/t)ide reverse transcriptase (NRTIs) Didanosine
English: HIV ANTIRETROVIRALS Integrase strand transfer inhibitors Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔*
Maltese: HIV Impedituri ta' integrase strand transfer Dolutegravir dolutegravir AUC ↓ 22% dolutegravir C24h ↓38% dolutegravir Cmax ↓ 11% darunavir ↔*
English: Unlike ritonavir, cobicistat does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or UGT1A1.
Maltese: B'kuntrast ma' ritonavir, cobicistat ma jinduċix CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 jew UGT1A1.
English: Interaction table
Maltese: Tabella ta'interazzjoni
English: Date of first authorisation: 26 January 2018
Maltese: Data tal-ewwel awtorizzazzjoni: 26 ta' Jannar 2018
English: Imputations according to the TLOVR algorithm Based on a normal approximation of the difference in % response Clades A1, D, F1, G, K, CRF02_AG, CRF12_BF, and CRF06_CPX Difference in means
Maltese: Ibbażat fuq l-approssimazzjoni normali tad-differenza fil-% tar-rispons Gruppi ta' virusis ġejjin mill-istess antenat A1, D, F1, G, K, CRF02_AG, CRF12_BF, u CRF06_CPX Differenza fil-medji
English: Rosuvastatin 10 mg once daily rosuvastatin AUC ↑ 48% rosuvastatin Cmax ↑ 144%
Maltese: Rosuvastatin 10 mg darba kuljum rosuvastatin AUC ↑ 48% rosuvastatin Cmax ↑ 144%
English: MedDRA system organ class Frequency category
Maltese: Klassi tas-sistemi u tal-organi MedDRA Kategorija ta' frekwenza
English: (MATE1 inhibition)
Maltese: (inibizzjoni ta' MATE1)